Analyst Price Target is $76.50
▲ +125.93% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Greenwich LifeSciences in the last 3 months. The average price target is $76.50, with a high forecast of $78.00 and a low forecast of $75.00. The average price target represents a 125.93% upside from the last price of $33.86.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Greenwich LifeSciences.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.